{"schema_version":"secwatch.filing_event.v1","accession":"0001736730-25-000021","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.664980+00:00","generated_at":"2026-05-24T03:59:23.845571+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CAMP4 reports FY2024 net loss $51.8M; cash $64M, Phase 1 data expected Q4 2025","bullets":["Net loss of $51.8M for FY2024 vs $49.3M in FY2023; R&D expenses $38.8M, G&A $14.9M.","Cash and equivalents $64.0M as of Dec 31, 2024; sufficient to fund into Q2 2026.","Phase 1 trial of CMP-CPS-001 for UCDs ongoing; SAD completed safely, MAD dosing in progress; safety, PK, PD data expected Q4 2025.","Phase 1b trial in female OTC heterozygotes expected Q2 2025 in Australia, Europe to follow.","Development candidate CMP-SYNGAP-01 nominated for SYNGAP1-related disorders; GLP tox studies planned 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001736730-25-000021","json":"https://secwatch.observer/filing/0001736730-25-000021.json","markdown":"https://secwatch.observer/filing/0001736730-25-000021.md","text":"https://secwatch.observer/filing/0001736730-25-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/0001736730-25-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000173673025000021/camp-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:59:23.845571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}